Pharmaceuticals and the developing world.

Pharmaceuticals have greatly improved health in developing countries, but many people in developing countries do not obtain even inexpensive pharmaceuticals and little pharmaceutical R&D is oriented toward products needed by developing countries, such as a malaria vaccine. Access to existing products could be improved by facilitating differential pricing, for example by subsidizing donation programs, and reforming health care delivery. R&D incentives could be improved if rich countries or international organization committed to purchase needed products when they are developed and make them available to the poor.

[1]  M. Kremer,et al.  Worms: Education and Health Externalities in Kenya , 2001 .

[2]  A. Phadke.  Drug Supply and Use: Towards a Rational Policy in India , 1998 .

[3]  H. Kettler,et al.  Updating the Cost of a New Chemical Entity , 1999 .

[4]  M. Nichter,et al.  Pharmacies, self-medication and pharmaceutical marketing in Bombay, India. , 1998, Social science & medicine.

[5]  Elliot Marseille,et al.  Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa , 1999, The Lancet.

[6]  J. Walley,et al.  Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan , 2001, The Lancet.

[7]  K. Leonard.  When Both States and Markets Fail: Asymmetric Information and the Role of NGOs in African Health Care , 2002 .

[8]  Violaine S. Mitchell,et al.  The children's vaccine initiative : achieving the vision , 1993 .

[9]  Robert S. Desowitz,et al.  The malaria capers : more tales of parasites and people, research and reality , 1991 .

[10]  S. Rose-Ackerman.  THE ROLE OF WAGES AND AUDITING DURING A CRACKDOWN ON CORRUPTION IN THE CITY OF BUENOS AIRES * , 2003 .

[11]  A. Attaran,et al.  Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? , 2001, JAMA.

[12]  Carl T. Bergstrom,et al.  The Red King effect: When the slowest runner wins the coevolutionary race , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Pécoul,et al.  Access to essential drugs in poor countries: a lost battle? , 1999, JAMA.

[14]  M. Kremer.  Creating Markets for New Vaccines. Part II: Design Issues , 2000, Innovation Policy and the Economy.

[15]  S. Preston,et al.  The changing relation between mortality and level of economic development. 1975. , 1975, Bulletin of the World Health Organization.

[16]  Iain M. Cockburn,et al.  New Pills for Poor People? Empirical Evidence after GATT , 2001 .

[17]  A. Batson,et al.  Private investment in AIDS vaccine development: obstacles and solutions. , 2001, Bulletin of the World Health Organization.

[18]  Daron Acemoglu,et al.  Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .

[19]  Milton Friedman,et al.  Free to Choose , 1980 .

[20]  M. Nichter.  Anthropology and International Health: Asian Case Studies , 1989 .

[21]  D. Daniels,et al.  Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units. , 2001, AIDS patient care and STDs.

[22]  M. Sprangers,et al.  Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. , 2001, Archives of internal medicine.

[23]  R. Gordon,et al.  The Estimation of Prewar Gross National Product: Methodology and New Evidence , 1989, Journal of Political Economy.

[24]  M. Altfeld,et al.  Consensus statement on antiretroviral treatment for AIDS in poor countries. , 2001 .

[25]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[26]  R. Fogel.  Nutrition and the Decline in Mortality Since 1700: Some Preliminary Findings , 1984 .

[27]  Dora L. Costa.  Estimating Real Income in the United States from 1888 to 1994: Correcting CPI Bias Using Engel Curves , 2001, Journal of Political Economy.

[28]  A. Wu,et al.  Self‐Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection , 2001, Journal of acquired immune deficiency syndromes.

[29]  C. Bell,et al.  Are pharmaceuticals cost-effective? A review of the evidence. , 2000, Health affairs.

[30]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[31]  Michael Kremer,et al.  Creating Markets for New Vaccines. Part I: Rationale , 2000, Innovation Policy and the Economy.

[32]  M. Ainsworth.  Confronting AIDS : public priorities in a global epidemic , 1997 .

[33]  鳥居 泰彦,et al.  世界経済・社会統計 = World development indicators , 1998 .